Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Bristol Myers Squibb, Cobenfy
Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has borne fruit with the approval of a promising new drug. | Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has borne fruit with the approval of a promising new schizophrenia drug.
Bristol-Myers Squibb’s Cobenfy Launch Spurs ‘Buy’ Rating Amid Favorable Market Dynamics
Analyst Chris Shibutani from Goldman Sachs reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report) and keeping the price
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic drugs.
ENDPOINTS NEWS
14h
Endpoints 11 winner Seaport Therapeutics: The Karuna team is back with another big bet in neuroscience
CEO Daphne Zohar Total raised $100 million Headquarters Boston, MA On Thursday, members of Seaport Therapeutics’ founding ...
Hosted on MSN
14d
Bristol Myers to Purchase Karuna
Bristol Myers Squib (NYSE:BMY) on Friday agreed to buy
Karuna
Therapeutics
(NASDAQ:KRTX) for $14 billion in cash, gaining a promising experimental schizophrenia drug to power growth as patents on ...
STAT
1h
Why are Genentech cancer researchers worried?
What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Promotes watch collection
'Harry Potter' star dies
World's oldest cheese found
Killer gets life sentence
50/50 ball ownership suit
Boxes to distribute Narcan
Ending password-sharing
Producing doc on Diddy
Urgent safety alert for 737s
Targeted Black residents?
Fake Biden robocalls fine
Stadiums to serve as shelters
More executives leave
On Secret Service failures
Chinese submarine sank
NC board removes 747K
NIH finds misconduct
Arrives in Luxembourg
WI duplicate ballot flap
Capital goods orders up
Rose announces retirement
Military recruiting rebounds
RU hits Ukraine's power grid
Feedback